Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | OGA | O60502 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5202526 | 0.95 | RAB9A (0.67) | RAB9ANPC1KMT2ACRBNL3MBTL1 | |
| SCHEMBL3895677 | 0.88 | RAB9A (0.72) | RAB9ANPC1KMT2ACRBNL3MBTL1 | |
| SCHEMBL7326778 | 0.87 | RAB9A (0.71) | RAB9ANPC1KMT2ACRBNL3MBTL1 | |
| SCHEMBL3099987 | 0.86 | RAB9A (0.66) | RAB9ANPC1KMT2ACRBNL3MBTL1 | |
| SCHEMBL20339428 | 0.86 | KMT2A (0.74) | RAB9ANPC1KMT2ACRBNL3MBTL1 | |
| SCHEMBL9205767 | 0.85 | HRH3 (0.58) | RAB9ANPC1KMT2ACRBNL3MBTL1 | |
| SCHEMBL9210857 | 0.85 | P2RY12 (0.65) | RAB9ANPC1KMT2AL3MBTL1OGA | |
| SCHEMBL9211056 | 0.85 | KMT2A (1.00) | RAB9ANPC1KMT2ACRBNOGA | |
| SCHEMBL7528163 | 0.85 | KMT2A (0.68) | RAB9ANPC1KMT2ACRBNL3MBTL1 | |
| SCHEMBL21776925 | 0.84 | RAB9A (0.59) | RAB9ANPC1KMT2AL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220281833-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2022-09-08 | — | — | US | disclosed |
| US-20200377465-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2020-12-03 | — | — | US | disclosed |
| US-20200377465-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2020-12-03 | — | — | US | disclosed |
| US-10774056-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774056-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190330169-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2019-10-31 | — | — | US | disclosed |
| US-20190330169-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2019-10-31 | — | — | US | disclosed |
| EP-3544969-A1 | PIPERAZINE DERIVATIVES AS SELECTIVE HDAC1,2 INHIBITORS | Regenacy Pharmaceuticals, LLC (US) | 2019-10-02 | — | — | EP | disclosed |
| WO-2003097047-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
| EP-0885886-B1 | PYRIDINECARBOXAMIDE DERIVATIVES | NISSHIN SEIFUN GROUP INC (JP) | 2002-05-29 | — | — | EP | disclosed |
| US-5972943-A | N-(NITRIC ACID,C14-18 ALKYL ESTER)-6-(1-(OPTIONALLY 4-SUBSTITUTED PIPERAZINYL)) PYRIDINE-3-CARBOXAMIDES; METHOD OF SYNTHESIS; ADMINISTERING TO TREAT CEREBRAL EDEMA; NO HYPOTENSIVE SIDE EFFECT | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1999-10-26 | — | — | US | disclosed |
| EP-0885886-A1 | NOVEL PYRIDINECARBOXAMIDE DERIVATIVES | Nisshin Flour Milling Co., Ltd. (JP) | 1998-12-23 | — | — | EP | disclosed |
| EP-0385351-B1 | Nicotinic acid derivatives and pharmaceutical compositions comprising same | NISSHIN FLOUR MILLING CO (JP) | 1995-01-11 | — | — | EP | disclosed |
| EP-0385350-B1 | Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same | NISSHIN FLOUR MILLING CO (JP) | 1994-11-30 | — | — | EP | disclosed |
| US-5025012-A | Cardiovascular disorders; antiischemic agents | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1991-06-18 | — | — | US | disclosed |
| US-4994456-A | Hypotensive agents | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| EP-0385351-A1 | Nicotinic acid derivatives and pharmaceutical compositions comprising same | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1990-09-05 | — | — | EP | disclosed |
| EP-0385350-A1 | Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1990-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | RAB9A 3228/4885NPC1 512/4885KMT2A 130/4885 |
| US-20220281833-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | RAB9A 3128/4885NPC1 623/4885KMT2A 92/4885 |
| US-10774056-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | RAB9A 3298/4885NPC1 774/4885KMT2A 79/4885 |
| US-20200377465-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | RAB9A 3128/4885NPC1 623/4885KMT2A 92/4885 |
| US-20190330169-A1 | SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | RAB9A 2395/4885NPC1 512/4885KMT2A 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.